An intravenous, every-2-weeks protein biologic CAR T-cell engager that binds the anti-CD19 CAR on previously infused CAR T cells and simultaneously binds antigens on malignant B cells, bridging them to form an immune synapse to reactivate and expand residual CD19-CAR T cells and redirect them to tumor cells.